GBT
Tokenize Commencing
Open
Public Research
in
Kirlian Electrophotography Technique
San Diego, CA --
November 12, 2020 -- InvestorsHub NewsWire
-- GBT Technologies Inc.
(OTC
PINK: GTCH)
("GBT", or the "Company"), announced that GBT Tokenize
("GBT/Tokenize) started research in
the Kirlian
Electrophotography
imaging technique potentially
aimed
for inclusion within
its qTerm device.
GBT/Tokenize's
qTerm,
is
a human
vitals device powered by AI and
is aimed
to measure human vitals with a touch of a
finger.
GBT/Tokenize
encourages public participation in its research. Scientists and
researchers that are interested to participate in our research are
welcome to send us their material for evaluation at
kirlian_research@qterm.me
The human body emits
various radiations such as infrared, electromagnetic radiation, low
level visible light and ultraviolet radiation. This human biofield
carries unique information which can potentially
be useful
for diagnosing and predicting diseases. The various aspects of this
biofield can be measured in order to identify organ and/or tissue
dysfunctions and therefore potentially
detect
early stages of possible diseases. Early detection is essential to
ensure proper treatment and care.
Kirlian
Electrophotography technique is a photographic method to capture
the phenomenon of electrical coronal discharges which can be used
to produce a human's organ biofield. The technique is based on
shooting a high voltage charge through an object that is connected
to a photographic plate. The resulting image typically includes a
colored aura around the object. When performed on a human
organ the
aura is
its biofield. The research will be focusing on using Kirlian
imaging techniques for early disease diagnostics.
GBT/Tokenize's
Machine Learning system is aimed to analyze the biofield data and
possible detection of onset disease. Based on Kirlian
images
and patterns, GBT/Tokenize's
AI seeks
to
observe, study, analyze and ultimately alert physicians about
possible underlying illnesses or
symptoms. If developed and
commercialized, such a system can be
efficient for remote telemedicine diagnostics and medical
advice.
"We are excited to
start new research for our qTerm device" stated Danny Rittman,
GBT's CTO. "This research is about the analysis of Kirlian
electrophotography data in order to detect an
onset of possible illnesses. Kirlian
imaging can produce a bio-energy of
human's organs and can perform as a diagnostic tool. Using Kirlian
imaging, we believe
it is
possible to produce a measure of
human
energy levels and examine changes in the energy distribution
throughout the organ(s). We are attempting to
determine if we can implement Kirlian
imaging
for qTerm by
means
of
producing
a human's finger aura (i.e. its
biofield). Along with qTerm
vitals measurement, the goal is to
potentially
provide
a
Kirilian
image.
In turn,
using
our Machine
learning technology, we are seeking
to develop an analysis
of the biofield
and,
in turn,
provide
a diagnostic
and potential medical issues classification.
We
believe this
type
of system,
if fully
developed and
commercialized, could
be
very
efficient as
additional diagnostic
system. We commenced our
research and we encourage public
participation in this
research
and we
will share our findings on our website qterm.me" continued Dr.
Rittman.
Illustration
of Kirlian photograph of
a fingertip, 1989*)
*) Source -
https://en.wikipedia.org/wiki/Kirlian_photography
Actual Test
imaging (for presentation
purposes only):
Forward-Looking
Statements
Certain statements
contained in this press release may constitute "forward-looking
statements".
Forward-looking
statements provide current expectations of future events based on
certain assumptions and include any statement that does not
directly relate to any historical or current fact. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors as disclosed in
our filings with the Securities and Exchange Commission located at
their website (
http://www.sec.gov).
In
addition to these factors, actual future performance, outcomes, and
results may differ materially because of more general factors
including (without limitation) general industry and market
conditions and growth rates, economic conditions, governmental and
public policy changes, the Company's ability to raise capital on
acceptable terms, if at all, the Company's successful development
of its products and the integration into its existing products and
the commercial acceptance of the Company's
products.
The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change.
However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact:
Dr. Danny
Rittman, CTO
GBT
Technologies Inc.